(Q54778813)

3 June 2018

editorial

0 references

title

Setting future standards for KRAS testing in colorectal cancer. (English)

1 reference

3 June 2018

1 reference

Han van Krieken

1

1 reference

3 June 2018

Jolien Tol

series ordinal

2

1 reference

3 June 2018

publication date

1 January 2009

1 reference

3 June 2018

published in

Pharmacogenomics

1 reference

3 June 2018

volume

10

1 reference

3 June 2018

issue

1

1 reference

3 June 2018

page(s)

1-3

1 reference

3 June 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.1

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.1

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.1

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.1

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.1

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.1

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.1

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.1

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.1

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.1

Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.1

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.1

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.1

21 January 2018

Identifiers

DOI

10.2217/14622416.10.1.1

1 reference

3 June 2018

1 reference

3 June 2018